(NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative ...
The FOXA1 protein is a potentially highly sensitive diagnostic marker for small cell carcinoma of the prostate and possibly ...
Tevard Biosciences, Inc., a biotechnology company pioneering tRNA-based therapies to cure a broad range of genetic diseases, ...
Regenxbio is pitching at FDA approval next year for its Duchenne muscular dystrophy (DMD) gene therapy RGX-202, after ...
Regenxbio (RGNX) stock drops after the company posted late-stage trial data for RGX-202, a gene therapy targeting Duchenne ...
Regenxbio’s gene therapy for Duchenne muscular dystrophy has smashed the primary endpoint of its pivotal trial, securing a ...
CMP-002 administration resulted in a statistically significant improvement in seizure phenotypes and parameters in a SYNGAP1 haploinsufficient mouse model ...
Optimized additive selection could help yeast-based cell-free protein expression systems fulfill their potential at commercial scale.
A long-overlooked stretch of the human genome appears to play a distinct role in shaping the social and stereotypic ...
2d
Chinese Neurosurgical Journal Reports KRAS Gene as Key Driver for Brain Arteriovenous Malformation
A recent study shows altered gene expression associated with brain arteriovenous malformation pathogenesis in HMEC‑1 ...
New kit offers researchers and development teams a meaningful advance in expression speed and output BOSTON, May 13, 2026 ...
New kit offers researchers and development teams a meaningful advance in expression speed and output BOSTON, May 12, 2026 /PRNewswire/ -- GenScript Biotech Corporation announced the launch of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results